Characteristics of patients and GMP in NSCLC
| No. of patients (%) | No. of patients (%) according to GMP status | |||
|---|---|---|---|---|
| GMP- negative | GMP- positive | P | ||
| All patients | 236 (100%) | 176 (74.6%) | 60 (25.4%) | |
| Age (mean ±SD) | 62.4± 9.7 | 62.7± 9.6 | 61.7± 10.0 | 0.489 |
| Gender | ||||
| Male | 170 (72.0%) | 128 (75.3%) | 42 (24.7%) | 0.740 |
| Female | 66 (28.0%) | 48 (72.7%) | 18 (27.3%) | |
| Performance status (PS) | ||||
| 0 | 206 (87.3%) | 156 (75.7%) | 50 (24.3%) | 0.485 |
| 1 | 28 (11.9%) | 19 (67.9%) | 9 (32.1%) | |
| 2 | 2 (0.8%) | 1 (50.9%) | 1 (50.0%) | |
| Histologic type | ||||
| Sq | 85 (36.0%) | 65 (76.5%) | 20 (23.5%) | 0.529 (Sq vs. Ad) |
| Ad | 130 (55.1%) | 94 (72.3%) | 36 (27.7%) | |
| Large cell carcinoma | 13 (5.5%) | 12 (92.3%) | 1 (7.7%) | |
| Others | 8 (3.4%) | 5 (62.5%) | 3 (37.5%) | |
| p-stage | ||||
| I | 138 (58.5%) | 101 (73.2%) | 37 (26.8%) | 0.265 (for all p-stage) |
| II | 26 (11.0%) | 17 (65.4%) | 9 (34.6%) | |
| IIIA | 72 (30.5%) | 58 (80.6%) | 14 (19.4%) | |